Diabetes News

Eli Lilly and Company and Adocia announce a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes

Scientists argue that scientific and political changes will make adaptive pathways the preferred approach to make new treatments available (European Medicines Agency)

Japan is the first country with a regulatory filing for omarigliptin. Worldwide, Merck is supporting omarigliptin with a clinical development program that includes nine Phase 3 clinical trials involving approximately 7,500 patients with type 2 diabetes in support of planned regulatory filings (Merck)

The fourth Access to Medicine Index report provides a finely detailed picture of how the world’s 20 largest research-based pharmaceutical companies address access to medicine. (Access to Medicine Foundation)

A new study is planned for the Diamyd® diabetes vaccine that will comprise 80 children with high risk of presenting with type 1 diabetes. The aim is to test whether the diabetes vaccine can prevent or delay the onset in the children (Diamyd)

Demonstrates Proof-of-Concept for ORMD-0801 Oral Insulin to Reduce Exogenous Insulin Requirements (Oramed Pharmaceuticals)

The New Mission T1D app, created by Sanofi Diabetes to address the need for greater understanding of T1D amongst children, parents and carers, friends and in the school environment is now available, free of charge, from the Apple UK store (Sanofi)

The three-year research collaboration will develop small molecule candidates from their respective portfolios (Mitsubishi Tanabe)

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015 (MannKind)

Continuing an open and honest debate – Alison Clough, ABPI Executive Director – Commercial UK, responds to NICE Chairman, David Haslam’s, interview with Pharmafocus last month

The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help people with diabetes better manage their condition (Sanofi)

MSD and Samsung Bioepis announce that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon (Merck)

AstraZeneca announce that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance (AstraZeneca)

A Phase 2a clinical trial for ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes met all primary and secondary endpoints (Oramed)

Bristol-Myers Squibb Company announce that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca (Bristol-Myers Squibb)

Bristol-Myers Squibb and AstraZeneca said they would pull a new diabetes drug from the German market because they had failed to agree on a price with a body of medical insurers. The decision to stop marketing oral drug dapagliflozin in Germany comes just a day after it was endorsed by an advisory panel to the U.S. Food and Drug Administration (Reuters)

MannKind Corporation announces the resubmission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder with an indication to improve glycemic control in adults with type 1 or type 2 diabetes (MannKind Corporation)